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The aim of the present study was to improve solubility and dissolution of the poorly aqueous soluble drug, etoricoxib by solvent
evaporation technique using various sugar carriers, such as lactose, sucrose, and mannitol. Etoricoxib solid dispersions and
their respective physical mixtures using lactose, sucrose, and mannitol were prepared in diﬀerent ratios by solvent evaporation
technique. The percent yield, drug content, saturation solubility, and in vitro dissolution of etoricoxib solid dispersions and
physical mixtures were analyzed. Etoricoxib solid dispersions were characterized by FTIR spectroscopy, XRD, and DSC analysis.
The FTIR spectroscopic analysis revealed the possibility of intermolecular hydrogen bonding in various solid dispersions. The
XRD and DSC studies indicated the transformation of crystalline etoricoxib (in pure drug) to amorphous etoricoxib (in solid
dispersions) by the solid dispersion technology. Both the aqueous solubility and dissolution of etoricoxib were observed in all
etoricoxibsoliddispersionsascomparedwithpureetoricoxibandtheirphysicalmixtures.Theinvitrodissolutionstudiesexhibited
improved dissolution in case of solid dispersion using lactose than the solid dispersions using both sucrose and mannitol. The in
vitro dissolution of etoricoxib from these solid dispersions followed Hixson-Crowell model.
1.Introduction
Poorly aqueous soluble drugs are usually characterized by a
low bioavailability due to less absorption, which is a major
concern of pharmaceutical industries worldwide. Attempts
to improve the solubility of these drug candidates have been
performed by various approaches [1]. Among them, solid
dispersion technique has attracted considerable interest as
an eﬃcient means of improving the dissolution rate, which
increases the bioavailability of a range of poorly aqueous
soluble drugs [2–4]. Fast and immediate drug dissolution
from solid dispersions has been observed due to increased
wettability, improved dispersibility of drug particles, and
existence of the drug in amorphous form with improved
solubility and absence of aggregation of drug particles using
various hydrophilic carriers [1–4].
Etoricoxib, 5-chloro-6 -methyl-3 [4-(methyl sulfonyl)
phenyl]-2, 3 –bypyridine, is a highly selective second gen-
eration cyclooxygenage-2 (COX-2) inhibitor administered
orally as an analgesic and nonsteroidal anti-inﬂammatory
drug (NSAID) (Figure 1)[ 5]. Etoricoxib is an eﬀective
analgesic drug that has shown some improved eﬃcacy versus
traditional NSAIDs [6]. It is used in the treatment of rheu-
matoid arthritis, osteoarthritis, postoperative dental pain,
chronic back pain, and acute gout [7, 8]. Moreover, recent
studies evidenced its eﬃcacy in patients with ankylosing
spondylitis [6]. But it’s very low aqueous solubility and poor
dissolution can cause formulation problems and limit its
therapeutic application by delaying the rate of absorption
and the onset of action [7, 9]. Therefore, improvements in
solubility and/or dissolution rate of etoricoxib may be
achieved through the preparation of solid dispersions. In
the literature, various solid dispersions of etoricoxib are
reported for improving the dissolution of etoricoxib using
various carriers like polyvinyl pyrrolidone K 30 (PVP K 30)
[10], polyethylene glycol 4000 (PEG 4000) and polyvinyl
pyrrolidone K 30 (PVP K 30) combination [11], Poloxamer
188 [12], and Gelucire 50/13, Compritol, and Sterotex K
NF [13]. In the literature, various solid dispersions using
sugars as carriers are reported [14–21]. In an investigation,
Dha et al. have prepared etoricoxib solid dispersions using
mannitol as carriers [22]. But, no attempt has been taken2 ISRN Pharmaceutics
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Figure 1: Chemical structure of etoricoxib.
to prepare solid dispersion of etoricoxib using other com-
mon sugars like lactose and sucrose as carriers for solid
dispersion of etoricoxib to improve the aqueous solubility
and dissolution enhancement of etoricoxib till now. The
enhancementof drugdissolution fromsugar-basedsolid dis-
persions is mainly attributed to increase in surface area of
drug exposed to large carrier molecules, increase wettability,
and consequently solubility due to polar eﬀect of sugars con-
taining polar groups [1]. Again, sugars like lactose, sucrose,
mannitolandsoforth,arelessexpensive,easilyavailable,and
commonlyusedexcipientsintabletandcapsuleformulations
than other carriers used for the preparation of solid disper-
sion. So, the use of sugars as carriers for the preparation of
soliddispersionsofdrugcandidatesmaybeabletoreducethe
production cost of the dosage forms, formulated using these
low-cost sugar-based solid dispersions of drugs. Therefore,
sugars as the suitable carriers for the preparation of solid
dispersion were used in the present investigation. So, the aim
of the present investigation is to prepare and characterize
etoricoxib solid dispersion using various sugars like lactose,
sucrose, and mannitol as carriers for improvements of
solubility and/or dissolution of poor aqueous soluble drug,
etoricoxib. Therefore, the objectives of this investigation are:
(i) preparation of etoricoxib solid dispersions using lactose,
sucrose and mannitol as carriers by solvent evaporation
technique, (ii) characterization of prepared solid dispersions
by Fourier transform infrared (FTIR) spectroscopy, X-ray
diﬀraction (XRD), and diﬀerential scanning calorimetry
(DSC) studies, and (iii) estimation of drug solubility and
dissolution of prepared etoricoxib solid dispersions and
comparing these data with that of pure drug and physical
mixtures of drug carriers.
2.MaterialsandMethods
2.1. Materials. Etoricoxib was obtained as a gift sample from
Cadila Healthcare Ltd., Moraiya, India. Lactose, sucrose,
mannitol, potassium dihydrogen phosphate, and sodium
hydroxide were purchased from S.D. Fine Chemicals Ltd.,
Mumbai, India. Ethanol (Bengal Chemicals and Pharmaceu-
ticals Ltd., Kolkata, India) was used. All reagents were of
A.R. graded. Double distilled water was used throughout the
experiment.
2.2. Preparation of Etoricoxib Physical Mixtures Using Sugars.
Physical mixtures of etoricoxib were prepared by mixing
etoricoxib with lactose, sucrose, and mannitol in 1:1 and
1:5 ratios in a glass mortar by mixing for 10 minutes.
2.3. Preparation of Etoricoxib Solid Dispersions Using Sugars.
Solid dispersions of etoricoxib were prepared by solvent
evaporation technique using various sugars like lactose,
sucrose, and mannitol as carriers in 1:1 and 1:5 ratios.
Etoricoxib was dissolved in ethanol to get clear solution.
Lactose, sucrose, and mannitol were dispersed as ﬁne par-
ticles and the solvent was removed by evaporation on a water
bath at 60◦C. The dried mass was stored in desiccator until
constant mass was obtained, crushed, and passed through
sieve no. 22.
2.4. Determination of Percent Yield. The percent yield of
etoricoxib solid dispersions was determined by using the
following formula:
percent yield =
Weight of prepared solid dispersion
Weight of drug + carriers
×100.
(1)
2.5. Determination of Percent Drug Content. Solid disper-
sions of etoricoxib (25mg) were placed in 25mL volumetric
ﬂask. Ethanol (10mL) was added, mixed thoroughly using a
rotating shaker for 1hour. The volume was made up to the
mark with ethanol. The solution was suitably diluted with
ethanol and spectrophotometrically assayed for drug content
at 233.5nm using the following formula:
percent drug content
=
Practical drug content in solid dispersions
Theoretical drug content in solid dispersions
×100.
(2)
2.6. Determination of Saturation Solubility. To evaluate the
increase in solubility of etoricoxib from solid dispersions,
saturation solubility measurements were conducted and
compared these data with that of pure etoricoxib and
physical mixtures of respective ratios. The known excess
samples (etoricoxib solid dispersions, physical mixtures, and
pure etoricoxib) containing 10mg equivalent weight of etor-
icoxib were added to 10mL of phosphate buﬀer, pH = 7.4,
and these samples were rotated at 20rpm in a water bath
(37 ± 0.5◦C) for 48 hours. The samples were then ﬁltered,
suitablydiluted,andanalyzedbyUV-VISspectrophotometer
(Shimadzu Corporation, Japan) at 284 nm wavelength.
2.7. Characterization
2.7.1. Fourier Transform-Infrared (FTIR) Spectroscopy. Phys-
icochemical characterization was performed using Fourier
transform-infrared (FTIR) spectroscopy. For this purpose,
samples were reduced to powder and analyzed as KBr pellets
by using a FTIR spectrometer (Shimadzu Corporation,
Japan).ISRN Pharmaceutics 3
Table 1: Percent yield and percent drug content of etoricoxib solid dispersions.
Solid dispersion type Ratio Percent yield
(%)$ Percent drug content (%)$
Etoricoxib:lactose 1:1 88.13 ± 7.53 96.68 ± 1.99
1:5 91.18 ± 3.19 98.39 ± 2.42
Etoricoxib:sucrose 1:1 85.43 ± 2.43 97.94 ± 2.50
1:5 89.63 ± 3.62 98.60 ± 2.13
Etoricoxib:mannitol 1:1 83.09 ± 2.13 95.75 ± 2.91
1:5 86.51 ± 2.15 97.32 ± 0.85
$Mean ± SD, n = 3.
Table 2: Saturation solubility of diﬀerent etoricoxib solid dispersions along with pure etoricoxib and physical mixtures using same carriers
(Mean ± SD, n = 3).
Type Ratio
Saturation solubility (μg/mL)$
Physical mixtures Solid dispersions
1:1 91.65 ± 4.95 124.28 ± 1.93
Etoricoxib:lactose 1:5 98.27 ± 5.04 142.26 ± 2.01
1:1 84.91 ± 1.44 107.88 ± 2.87
Etoricoxib:sucrose 1:5 89.80 ± 4.12 120.42 ± 2.55
1:1 90.50 ± 5.20 118.82 ± 2.01
Etoricoxib:mannitol 1:5 95.76 ± 6.67 131.98 ± 3.48
Pure etoricoxib —
Saturation solubility (μg/mL)$
78.48 ± 1.47
$Mean ± Standard deviation, n = 3.
2.7.2.X-RayDiﬀraction(XRD). XRDpatternswererecorded
on an X diﬀractometer (Phillip PW 1130/00 diﬀractometer,
The Netherlands), employing CuK∞ radiation source oper-
ating at 30mA and 40kV. Samples were scanned from 6 to
40◦ 2θ at a scanning rate of 0.02◦ 2θ s−1.
2.7.3. Diﬀerential Scanning Calorimetry (DSC). The samples
were analyzed by diﬀerential scanning calorimeter (Mod-
el DT-60, Shimadzu) at a constant scanning speed of
10◦Cmin −1 from 0–300◦C. The 5–7mg samples were accu-
rately weighed into solid aluminium pans without seals.
2.8. In Vitro Dissolution Studies. In vitro dissolution studies
were performed in phosphate buﬀer (pH 7.4, 900mL) at
37 ± 0.5◦C, using USP XXIII apparatus (Electrolab, India)
with a paddle rotating at 50rpm. The samples (pure etor-
icoxib, etoricoxib physical mixtures, and etoricoxib solid
dispersions) equivalent to 60mg etoricoxib were subjected
to dissolution. At ﬁxed time intervals, samples (5mL) were
withdrawn and equal amount of fresh dissolution medium
was added. Withdrawn samples were ﬁltered (Whatman
ﬁlter paper no. 41) and spectrophotometrically assayed for
drug content at 284.0nm wavelengths using a UV-VIS spec-
trophotometer (Shimadzu Corporation, Japan).
3. Results andDiscussion
3.1. Percent Yield and Drug Content. Various etoricoxib solid
dispersions using sugars like lactose, sucrose, and mannitol
at diﬀerent ratios (1:1 and 1:5) were prepared by solvent
evaporation technique to increase the solubility and/or dis-
solution of poorly aqueous soluble drug, etoricoxib. The per-
cent yield of various etoricoxib solid dispersions was with-
in the range of 83.09 ± 2.13% to 91.18 ± 3.19% (Table 1).
The percentage drug content in various newly prepared
etoricoxib solid dispersions ranged from 95.75 ± 2.91% and
98.60 ± 2.13%, as reported in Table 1. This indicated that
etoricoxib was uniformly distributed in all of these prepared
solid dispersions.
3.2. Saturation Solubility. The saturation solubility of pure
etoricoxib, various newly prepared etoricoxib solid disper-
sions using sugars (lactose, sucrose, and mannitol), and their
respectivephysicalmixturesinphosphatebuﬀer,pH7.4were
measured. As etoricoxib has pH-dependent solubility [13],
the change in pH may hamper the results during solubility
measurement and in vitro drug release study. So, to maintain
pH constant, phosphate buﬀer, pH 7.4 was used. Pure
etoricoxibshowed78.48±1.47μg/mLofsaturationsolubility.
All of samples, both physical mixture and solid dispersions
of etoricoxib using sugars, showed an increase in drug
solubility (Table 2). All physical mixtures showed higher
saturation solubility as compared with pure etoricoxib.
Again, etoricoxib solid dispersions showed higher saturation
solubility than their respective physical mixtures of drug
and carrier. This might be attributable to an improvement
of wetting of drug particles and localized solubilization by
the water-soluble sugar carriers. In case of solid dispersions,4 ISRN Pharmaceutics
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Figure 2: Fourier transform-infra red (FTIR) spectra of pure etoricoxib (a) and drug to carrier ratio, 1:5 etoricoxib solid dispersions using
lactose (b), sucrose (c), and mannitol (d).
the order of sugar carriers for increasing saturation solubility
was lactose > mannitol > sucrose.
3.3. Characterization
3.3.1. FTIR Spectroscopy Analysis. FTIR spectroscopy analy-
siswasdonetoanalyzephysicochemicalinteractionsbetween
etoricoxibandsugarcarriersinformofsoliddispersions.FT-
IRspectraofpureetoricoxibandvariousetoricoxibsoliddis-
persions are shown in Figures 2(a), 2(b), 2(c),a n d2(d).T h e
FTIR spectra of pure etoricoxib showed characteristic peaks
at 1592.9cm−1 (C=N stretching vibration), 1430.0, 1299.4,
1136.8, and 1089.6cm−1 (S=O stretching vibration) and
834.0, 777.1, and 639.22009cm−1 (C–Cl stretching vibra-
tion). The FTIR spectrum of solid dispersions of etoricoxib
using sugars like lactose, sucrose, and mannitol revealed
a shift and slight broadening of 1291.3cm−1 (in case of
solid dispersions using lactose), 1290.6cm−1 (in case of solid
dispersions using sucrose), and etoricoxib and characteristic
O–H stretching of vibration peaks, 3350.7cm−1 (in case of
solid dispersions using lactose), 3349.7cm−1 (in case of solid
dispersions using sucrose), and 3292.8cm−1 (in case of solid
dispersions using mannitol) of carriers. These observations
might indicate the possibility of inter-molecular hydrogen
bonding via the S=O group of etoricoxib and O–H group of
sugar carriers.
3.3.2. XRD Analysis. The XRD patterns of pure etoricoxib
and various newly prepared etoricoxib solid dispersions
using sugars are presented in Figures 3(a), 3(b), 3(c),a n d
3(d). The characteristic peaks appeared in the XRD pattern
of the pure etoricoxib at a diﬀraction angle of 9.65, 11.40,
14.41, 16.70, 19.62, 22.75, 24.10, 29.52, and 31.44◦ (2θ),
suggesting that the drug is present as a crystalline state. The
XRD pattern of etoricoxib solid dispersions using lactose,
sucrose, and mannitol showed various characteristics peaks
of pure etoricoxib with/without very small shifting. It was
also observed that some peaks shown by pure etoricoxib
were absent, and the intensity of peaks of these etoricoxib
solid dispersions was found to be markedly reduced when
compared to that of the pure etoricoxib. These observations
indicate that the drug (etoricoxib) in solid dispersion was
amorphous as compared to the pure drug.
3.3.3. DSC Analysis. DSC analysis was done for pure etori-
coxib and solid dispersions of etoricoxib using lactose, the
sugar carrier which showed higher saturation solubility than
other sugars examined in this investigation. DSC patternISRN Pharmaceutics 5
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Figure 3: XRD pattern of pure etoricoxib (a) and drug to carrier ratio, 1:5 etoricoxib solid dispersions using lactose (b), sucrose (c), and
mannitol (d).
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Figure 4: DSC thermogram of lactose (a), pure etoricoxib (b), and
etoricoxib solid dispersions (c) using lactose (1:5).
of etoricoxib solid dispersion using lactose, pure etoricoxib
along with that of lactose are shown in Figure 4. The DSC
thermogram of pure etoricoxib showed a sharp endothermic
peak at 139.88◦C, which was ascribed to drug melting. The
DSC curve of lactose showed a sharp peak endothermic peak
at 151.88◦C, corresponding to the melting point of lactose.
The peak temperature in solid dispersion was shifted slightly
to lower temperature with respect to the drug, and there
was a decrease in ΔH value of etoricoxib solid dispersion
usinglactose(−256.34Jg−1)comparedtothepureetoricoxib
(−90.067 Jg−1). These phenomena could be attributed to the
amorphous form of the etoricoxib in solid dispersion.
3.4. In Vitro Dissolution. The in vitro dissolution proﬁles
of the drug (etoricoxib), various solid dispersions using
sugars, and their respective physical mixtures in phosphate
buﬀer (pH = 7.4) for 120 minutes are shown in Figures
5(a) to 5(c). All of the physical mixture and solid dispersion
samples showed improved dissolution of etoricoxib over
pure etoricoxib. The enhancement of dissolution is mainly
attributed to increased surface area of drug exposed to large
carrier molecules, increased wettability, and accordingly
solubility due to polar eﬀect of sugars containing polar
groups [1]. This also may be attributed to the higher
hydrophilic sugar carriers, which can reduce the interfacial
tension between the poorly aqueous soluble drug and the
dissolution medium [23]. Again, all of the solid dispersion
samples showed more improved etoricoxib dissolution than
their respective physical mixture samples. This observation
indicated that the increased dissolution of etoricoxib from
solid dispersion due to presence of drug in amorphous
state as compared to the physical mixtures and pure drug,
where drug is present in crystalline state [24]. In case of
etoricoxib solid dispersions, the order sugar carriers for
increasing dissolution in phosphate buﬀer (pH = 7.4) was6 ISRN Pharmaceutics
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Figure 5: (a) Comparative in vitro dissolution proﬁles of etoricoxib solid dispersions using lactose [SD-L (1:1), SD-L (1:5)], etoricoxib-
lactose physical mixtures [PM-L (1:1), PM-L (1:5)], and pure etoricoxib [ET] (Mean ± SD, n = 3). (b) Comparative in vitro dissolution
proﬁles of etoricoxib solid dispersions using sucrose [SD-S (1:1), SD-S (1:5)], etoricoxib-sucrose physical mixtures [PM-S (1:1), PM-S
(1:5)] and pure etoricoxib [ET] (Mean ± SD, n = 3). (c) Comparative in vitro dissolution proﬁles of etoricoxib solid dispersions using
mannitol [SD-M (1:1), SD-M (1:5)], etoricoxib-mannitol physical mixtures [PM-M (1:1), PM-M (1:5)], and pure etoricoxib [ET]
(Mean ± SD, n = 3). (d) Comparative in vitro dissolution proﬁles of etoricoxib solid dispersions using lactose [SD-L (1:5)], sucrose [SD-S
(1:5), and mannitol [SD-M (1:5)], and pure etoricoxib [ET] (Mean ± SD, n = 3).
lactose > mannitol > sucrose (Figure 5(d)) and this observa-
tionis wellcorrelatedwiththe resultsofsaturationsolubility.
3.5.DrugReleaseKineticsandMechanism. Inordertopredict
and correlate the mechanism and kinetics of etoricoxib
release from etoricoxib solid dispersions using sugars, it is
necessary to ﬁt into a suitable mathematical model. The
in vitro drug release data of these newly prepared solid dis-
persions were evaluated kinetically using various mathemat-
ical models like zero order, ﬁrst order, Higuchi, Hixson-
Crowell, and Korsmeyer-Peppas model [18, 25].
Zero-order model:
F = K0t,( 3 )
whereF representsthefractionofdrugreleasedintimet,and
K0 is the apparent release rate constant or zero-order release
constant.
First-order model:
ln(1 − F) =− K1stt,( 4 )
whereF representsthefractionofdrugreleasedintimet,and
K1 is the ﬁrst-order release constant.
Higuchi model:
F = KHt1/2,( 5 )
whereF representsthefractionofdrugreleasedintimet,and
KH is the Higuchi dissolution constant.
Hixson-Crowell model:
W1/3
0 −W1/3
t = Kt,( 6 )
where W0 and Wt represent initial mass, and mass remained
at time t,r e s p e c t i v e l y ;KHC is the rate constant.
Korsmeyer-Peppas model:
F = KPtn,( 7 )
where F represents the fraction of drug released in time t, KP
is the rate constant, and n is the diﬀusional exponent; this
indicates the drug release mechanism.ISRN Pharmaceutics 7
Table 3: Correlation coeﬃcient (R2) values in the analysis of dissolution data of etoricoxib solid dispersions using sugars.
Mathematical models
Formulation codes∗
SD-L (1:1) SD-L (1:5) SD-S (1:1) SD-S (1:5) SD-M (1:1) SD-M (1:5)
Zero-order model 0.9462 0.9681 0.9276 0.9389 0.9276 0.9502
First-order model 0.9846 0.9871 0.9599 0.9689 0.9718 0.9807
Higuchi model 0.9892 0.9852 0.9756 0.9782 0.9714 0.9824
Hixson-Crowell model 0.9943 0.9958 0.9886 0.9882 0.9837 0.9897
Korsmeyer-Peppas model 0.9870 0.9807 0.9754 0.9718 0.9728 0.9739
∗Formulation codes:
SD-L (1:1), and SD-L (1:5): etoricoxib solid dispersions using lactose
SD-S (1:1), and SD-S (1:5): etoricoxib solid dispersions using sucrose
SD-M (1:1), and SD-M (1:5): etoricoxib solid dispersions using mannitol.
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Figure 6: Hixson-Crowell’s dissolution plots of etoricoxib solid
dispersions using sugars SD-L (1:1), and SD-L (1:5): etoricoxib
solid dispersions using lactose; SD-S (1:1), and SD-S (1:5):
etoricoxib solid dispersions using sucrose; SD-M (1:1), and SD-M
(1:5): etoricoxib solid dispersions using mannitol.
The results of the curve ﬁtting into these above-men-
tioned mathematical models indicate the release behaviour
of etoricoxib from these newly prepared solid dispersions
(Table 3). When the correlation coeﬃcients of these math-
ematical models for etoricoxib release were compared, it
was found to follow Hixson-Crowell model with the best-ﬁt
correlation coeﬃcient value (R2 = 0.9839 to 0.9958). Again,
a plot of W1/3
0 −W1/3
t versus time using dissolution data was
drawn and it was found linear (Figure 6) with all etoricoxib
solid dispersions using various sugars like lactose, sucrose,
and mannitol. This observation indicates that the disso-
lution of etoricoxib from these newly prepared solid dis-
persions occurred from discretely suspended or deposited
(monodispersed) particles [26]. This might have also con-
tributed to the enhanced dissolution rate of etoricoxib from
solid dispersions using sugars as hydrophilic carriers.
4. Conclusion
Etoricoxib solid dispersions using various sugars like lactose,
sucrose, and mannitol were successfully prepared by solvent
evaporation technique. FTIR spectroscopy revealed the
possibility of intermolecular hydrogen bonding in various
solid dispersions. XRD and DSC observations indicated that
the transformation of crystalline etoricoxib (in pure drug)
to amorphous etoricoxib (in solid dispersions) by solid
dispersion technology. The saturation solubility and in vitro
dissolution studies showed a remarkable increase in both
the solubility and dissolution of etoricoxib solid dispersions
using sugars as compared with pure etoricoxib and their
physical mixtures. The in vitro dissolution studies of all these
newly prepared solid dispersions showed that the improved
solubility and dissolution in case of solid dispersion using
lactose than the solid dispersions using both sucrose and
mannitol. The in vitro dissolution of etoricoxib from these
soliddispersionswasfoundtofollowHixson-Crowellmodel.
Therefore, the solubility and dissolution of poorly aqueous
soluble etoricoxib can be enhanced by the preparation of
solid dispersions using sugars as hydrophilic carriers.
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